Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets in green
Thu, 22 Aug 01:30 pm

Indian stock markets have recovered losses and are now trading above the dotted line. Barring stocks from banking and realty, most of the sectoral indices are witnessing buying interest. Stocks from metal and oil and gas sectors are among the leading gainers.

BSE-Sensex is up by 295 points and NSE-Nifty is trading up by 80 points. While BSE Mid Cap is trading up by 0.09%, BSE Small Cap index is trading up by 0.09%. The rupee is trading at 64.91 to the US dollar.

Majority of the automobile stocks are trading in the red with Force Motors and Maruti Suzuki being the biggest losers. In order to arrest declining sales Tata Motors wants to refurbish its Nano model and re-position its earlier budget car image to a smart city car, as per a leading financial daily. According to data from Society of Automobile Manufacturers (SIAM), the market share of Tata Motors in passenger cars fell to 8.9% in July 2013 from 11.8% in March 2013. The company is currently operating at a capacity utilization of 48%. The company wants to add new features and improve the perceived value of Nano with every subsequent model launch. The company is planning to add features such as power steering, improved interiors and exteriors, fuel efficiency and CNG model to attract the urban youth. Nano sales has not been able to pick up despite discounts and freebies offered by the company on the model. The company made capital investments of Rs 30 bn last year and this year, the investments will be more. Tata Motors' stock is currently trading up by 2.7%.

Indian pharma Stocks are trading mixed, with Piramal enterprises and Indoco Remedies leading the losses while Ranbaxy laboratories and Orchid chemicals are the leading gainers. As per the financial daily, Cadila Healthcare has received final approval from the United States Food and Drug Administration (USFDA) to market Lansoprazole capsules in the US market. This approval is for Lansoprazole delayed release with 15mg and 30mg strengths. The said drug is used for treating ulcers and other conditions involving excessive stomach acid. The product had sales of $ 500 m per annum during 2012. Further, with this approval the company now has 81 approvals and has so far filed 186 abbreviated new drug applications (ANDAs). Among the other Indian companies Dr Reddy's also holds approval for this drug and has good market share. Cadila was trading down by 1.2% at the time of writing.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets in green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.